Amble vs VitaFusions IV
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Amble
Best for mainstream telehealth GLP-1 accessStarting at $179/mo
Side-by-Side Comparison
| Feature | Amble | VitaFusions IV |
|---|---|---|
| Overall Score | ✓7.4/10 | 7.0/10 |
| Starting Price | $179/mo | — |
| Editorial Rating | ✓3.7 ★ /5 | 3.5 ★ /5 |
| Features | ✓3 features | 1 features |
| States Available | ✓50 | 0 |
| Compounded | ✓ Yes | — |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Amble
Pros
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
Cons
- ✗Limited public information on program details
VitaFusions IV
Pros
- ✓Semaglutide confirmed from page metadata
Cons
- ✗Pending full verification — site is JS-rendered
Our Verdict
Amble edges out VitaFusions IV with a higher overall score of 7.4/10 and is particularly strong for mainstream telehealth GLP-1 access. VitaFusions IV remains a solid alternative, especially if you're looking for pending verification.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.